Acer Therapeutics, Inc. (Nasdaq: ACER), relating to its proposed merger with Zevra Therapeutics, Inc. Under the terms of the agreement, ACER shareholders are expected to receive 0.121 shares of Zevra per share they own, plus the possibility of additional non-transferable CVRs.